Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Limited announced the issuance of 52,078 performance rights set to expire in November 2028, as part of an employee incentive scheme. This move is aimed at motivating and retaining talent within the company, potentially enhancing its operational capabilities and competitive positioning in the biotechnology sector.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited operates in the biotechnology industry, focusing on the development and commercialization of regenerative medicine products. The company primarily targets the repair and regeneration of soft tissue injuries, catering to a market that seeks advanced medical solutions for tissue repair.
Average Trading Volume: 833,497
Technical Sentiment Signal: Buy
Current Market Cap: A$286M
For a thorough assessment of OCC stock, go to TipRanks’ Stock Analysis page.